Pilot trial of late booster doses of surfactant for ventilated premature infants

J. D. Merrill, P. L. Ballard, S. E. Courtney, D. J. Durand, A. Hamvas, A. M. Hibbs, K. W. Lu, R. M. Ryan, A. M. Reynolds, K. Spence, Robin H Steinhorn, W. E. Truog, E. C. Eichenwald, R. A. Ballard

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: Many premature infants at risk for bronchopulmonary dysplasia experience episodes of surfactant dysfunction with reduced surfactant protein B (SP-B). In this study, we investigated the safety and responses to booster doses of surfactant. Study Design: A total of 87 infants, 500 to 1250 g birth weight, who were ventilated at 7 to 10 days received 2 or 3 doses of Infasurf (Calfactant, Forest Pharmaceuticals, St Louis, MO, USA) within a 1-week period. Result: For 184 doses, occurrence rates of transient bradycardia (13) and plugged endotracheal tube (5) were low, and no other adverse effects were noted. Treatment transiently improved the respiratory severity score (FiO 2 × mean airway pressure), SP-B content (+75%) and surface properties of isolated surfactant. Levels of eight proinflammatory cytokines in tracheal aspirate were interrelated and unchanged from baseline after surfactant treatment. Conclusion: Booster doses of surfactant for premature infants with lung disease are safe and transiently improve respiratory status as well as composition and function of endogenous surfactant.

Original languageEnglish (US)
Pages (from-to)599-606
Number of pages8
JournalJournal of Perinatology
Volume31
Issue number9
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Premature Infants
Surface-Active Agents
Bronchopulmonary Dysplasia
Surface Properties
Bradycardia
Birth Weight
Lung Diseases
Cytokines
Safety
Pressure
Therapeutics
Pharmaceutical Preparations

Keywords

  • proinflammatory cytokines
  • surface tension
  • surfactant protein B
  • tracheal aspirate

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health

Cite this

Merrill, J. D., Ballard, P. L., Courtney, S. E., Durand, D. J., Hamvas, A., Hibbs, A. M., ... Ballard, R. A. (2011). Pilot trial of late booster doses of surfactant for ventilated premature infants. Journal of Perinatology, 31(9), 599-606. https://doi.org/10.1038/jp.2010.210

Pilot trial of late booster doses of surfactant for ventilated premature infants. / Merrill, J. D.; Ballard, P. L.; Courtney, S. E.; Durand, D. J.; Hamvas, A.; Hibbs, A. M.; Lu, K. W.; Ryan, R. M.; Reynolds, A. M.; Spence, K.; Steinhorn, Robin H; Truog, W. E.; Eichenwald, E. C.; Ballard, R. A.

In: Journal of Perinatology, Vol. 31, No. 9, 09.2011, p. 599-606.

Research output: Contribution to journalArticle

Merrill, JD, Ballard, PL, Courtney, SE, Durand, DJ, Hamvas, A, Hibbs, AM, Lu, KW, Ryan, RM, Reynolds, AM, Spence, K, Steinhorn, RH, Truog, WE, Eichenwald, EC & Ballard, RA 2011, 'Pilot trial of late booster doses of surfactant for ventilated premature infants', Journal of Perinatology, vol. 31, no. 9, pp. 599-606. https://doi.org/10.1038/jp.2010.210
Merrill JD, Ballard PL, Courtney SE, Durand DJ, Hamvas A, Hibbs AM et al. Pilot trial of late booster doses of surfactant for ventilated premature infants. Journal of Perinatology. 2011 Sep;31(9):599-606. https://doi.org/10.1038/jp.2010.210
Merrill, J. D. ; Ballard, P. L. ; Courtney, S. E. ; Durand, D. J. ; Hamvas, A. ; Hibbs, A. M. ; Lu, K. W. ; Ryan, R. M. ; Reynolds, A. M. ; Spence, K. ; Steinhorn, Robin H ; Truog, W. E. ; Eichenwald, E. C. ; Ballard, R. A. / Pilot trial of late booster doses of surfactant for ventilated premature infants. In: Journal of Perinatology. 2011 ; Vol. 31, No. 9. pp. 599-606.
@article{d224d1c0ee534866aa46dbb81e636a06,
title = "Pilot trial of late booster doses of surfactant for ventilated premature infants",
abstract = "Objective: Many premature infants at risk for bronchopulmonary dysplasia experience episodes of surfactant dysfunction with reduced surfactant protein B (SP-B). In this study, we investigated the safety and responses to booster doses of surfactant. Study Design: A total of 87 infants, 500 to 1250 g birth weight, who were ventilated at 7 to 10 days received 2 or 3 doses of Infasurf (Calfactant, Forest Pharmaceuticals, St Louis, MO, USA) within a 1-week period. Result: For 184 doses, occurrence rates of transient bradycardia (13) and plugged endotracheal tube (5) were low, and no other adverse effects were noted. Treatment transiently improved the respiratory severity score (FiO 2 × mean airway pressure), SP-B content (+75{\%}) and surface properties of isolated surfactant. Levels of eight proinflammatory cytokines in tracheal aspirate were interrelated and unchanged from baseline after surfactant treatment. Conclusion: Booster doses of surfactant for premature infants with lung disease are safe and transiently improve respiratory status as well as composition and function of endogenous surfactant.",
keywords = "proinflammatory cytokines, surface tension, surfactant protein B, tracheal aspirate",
author = "Merrill, {J. D.} and Ballard, {P. L.} and Courtney, {S. E.} and Durand, {D. J.} and A. Hamvas and Hibbs, {A. M.} and Lu, {K. W.} and Ryan, {R. M.} and Reynolds, {A. M.} and K. Spence and Steinhorn, {Robin H} and Truog, {W. E.} and Eichenwald, {E. C.} and Ballard, {R. A.}",
year = "2011",
month = "9",
doi = "10.1038/jp.2010.210",
language = "English (US)",
volume = "31",
pages = "599--606",
journal = "Journal of Perinatology",
issn = "0743-8346",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Pilot trial of late booster doses of surfactant for ventilated premature infants

AU - Merrill, J. D.

AU - Ballard, P. L.

AU - Courtney, S. E.

AU - Durand, D. J.

AU - Hamvas, A.

AU - Hibbs, A. M.

AU - Lu, K. W.

AU - Ryan, R. M.

AU - Reynolds, A. M.

AU - Spence, K.

AU - Steinhorn, Robin H

AU - Truog, W. E.

AU - Eichenwald, E. C.

AU - Ballard, R. A.

PY - 2011/9

Y1 - 2011/9

N2 - Objective: Many premature infants at risk for bronchopulmonary dysplasia experience episodes of surfactant dysfunction with reduced surfactant protein B (SP-B). In this study, we investigated the safety and responses to booster doses of surfactant. Study Design: A total of 87 infants, 500 to 1250 g birth weight, who were ventilated at 7 to 10 days received 2 or 3 doses of Infasurf (Calfactant, Forest Pharmaceuticals, St Louis, MO, USA) within a 1-week period. Result: For 184 doses, occurrence rates of transient bradycardia (13) and plugged endotracheal tube (5) were low, and no other adverse effects were noted. Treatment transiently improved the respiratory severity score (FiO 2 × mean airway pressure), SP-B content (+75%) and surface properties of isolated surfactant. Levels of eight proinflammatory cytokines in tracheal aspirate were interrelated and unchanged from baseline after surfactant treatment. Conclusion: Booster doses of surfactant for premature infants with lung disease are safe and transiently improve respiratory status as well as composition and function of endogenous surfactant.

AB - Objective: Many premature infants at risk for bronchopulmonary dysplasia experience episodes of surfactant dysfunction with reduced surfactant protein B (SP-B). In this study, we investigated the safety and responses to booster doses of surfactant. Study Design: A total of 87 infants, 500 to 1250 g birth weight, who were ventilated at 7 to 10 days received 2 or 3 doses of Infasurf (Calfactant, Forest Pharmaceuticals, St Louis, MO, USA) within a 1-week period. Result: For 184 doses, occurrence rates of transient bradycardia (13) and plugged endotracheal tube (5) were low, and no other adverse effects were noted. Treatment transiently improved the respiratory severity score (FiO 2 × mean airway pressure), SP-B content (+75%) and surface properties of isolated surfactant. Levels of eight proinflammatory cytokines in tracheal aspirate were interrelated and unchanged from baseline after surfactant treatment. Conclusion: Booster doses of surfactant for premature infants with lung disease are safe and transiently improve respiratory status as well as composition and function of endogenous surfactant.

KW - proinflammatory cytokines

KW - surface tension

KW - surfactant protein B

KW - tracheal aspirate

UR - http://www.scopus.com/inward/record.url?scp=80052342943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052342943&partnerID=8YFLogxK

U2 - 10.1038/jp.2010.210

DO - 10.1038/jp.2010.210

M3 - Article

C2 - 21311500

AN - SCOPUS:80052342943

VL - 31

SP - 599

EP - 606

JO - Journal of Perinatology

JF - Journal of Perinatology

SN - 0743-8346

IS - 9

ER -